Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Payables (2022 - 2025)

Stoke Therapeutics has reported Payables over the past 4 years, most recently at $4.9 million for Q4 2025.

  • Quarterly results put Payables at $4.9 million for Q4 2025, up 97.72% from a year ago — trailing twelve months through Dec 2025 was $4.9 million (up 97.72% YoY), and the annual figure for FY2025 was $4.9 million, up 97.72%.
  • Payables for Q4 2025 was $4.9 million at Stoke Therapeutics, down from $5.9 million in the prior quarter.
  • Over the last five years, Payables for STOK hit a ceiling of $5.9 million in Q3 2025 and a floor of $766000.0 in Q4 2022.
  • Median Payables over the past 4 years was $2.8 million (2023), compared with a mean of $3.0 million.
  • Biggest five-year swings in Payables: crashed 56.8% in 2023 and later skyrocketed 153.53% in 2024.
  • Stoke Therapeutics' Payables stood at $766000.0 in 2022, then skyrocketed by 121.28% to $1.7 million in 2023, then skyrocketed by 47.37% to $2.5 million in 2024, then surged by 97.72% to $4.9 million in 2025.
  • The last three reported values for Payables were $4.9 million (Q4 2025), $5.9 million (Q3 2025), and $4.3 million (Q2 2025) per Business Quant data.